Welcome to BioSeeker Group!

Biologicals

In this section you will find Therapeutics Line of Treatment Biologicals market research reports and publications. These provide information on the latest products, news, market growth forecasts, data and business opportunities of value to your organization.

17 Item(s)

per page

Set Ascending Direction
  1. Therapeutic Peptides in Oncology - Favorable Conditions But Where to Commercialize?

    $2,450.00
    Published by BioSeeker Group on May 28th, 2009
    This report is an important part of creating and implementing a market development plan for any cancer therapeutic peptide drugs to ensure that the optimal market conditions exist by the time the product is commercialized. Learn More

  2. The Global Competitive Landscape of Antibody Drug Development in Cancer: The Faster Route to Consider Your Options and Position of Others

    $2,450.00
    Published by BioSeeker Group on Sep 27th, 2011
    This report will excel your competitive awareness and decrease your decision making time in one of the fastest growing segments in the pharmaceutical market, namely antibodies for the treatment of cancer. Learn More

  3. RNA (miRNA, RNAi & siRNA) Therapy in Oncology Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 103 companies plus partners who are today developing 131 RNA (miRNA, RNAi & siRNA) drugs in 198 developmental projects in cancer across 103 different targets. In addition, there are 2 suspended drugs and another 39 drugs where development has been ceased. Learn More

  4. Proteins in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 455 companies plus partners who are today developing 521 protein drugs in 914 developmental projects in cancer across 229 different targets. In addition, there are 2 suspended drugs and another 207 drugs where development has been ceased. Learn More

  5. Peptides in Oncology: Analytical Tool

    $4,750.00
    Published by BioSeeker Group on Aug 22nd, 2016
    This Analytical Tool transforms your computer’s desktop into a high capacity workbench within the area of peptides. It supports you in making reports, presentations and preparing conference attendance and it is all done via an easy to use ’point and click’ interface. Learn More

  6. Peptides in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 340 companies plus partners who are today developing 356 peptide drugs in 778 developmental projects in cancer across 252 different targets. In addition, there are 4 suspended drugs and another 148 drugs where development has been ceased. Learn More

  7. Nucleic Acid Therapies in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 308 companies plus partners who are today developing 381 nucleic acid therapy drugs in 775 developmental projects in cancer across 251 different targets. In addition, there are 9 suspended drugs and another 211 drugs where development has been ceased. Learn More

  8. MicroRNAs in Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 567 companies plus partners who are today developing 841 microRNA targeting and competitor drugs in 3023 developmental projects in cancer across 289 different targets. In addition, there are 5 suspended drugs and another 343 drugs where development has been ceased. Learn More

  9. Commercializing Peptides in Cancer: The Faster Route to Consider Your Options and Position of Others

    $2,450.00
    Published by BioSeeker Group on Nov 14th, 2011
    This report will excel your competitive awareness and decrease your decision making time in managing peptide drug development in cancer. Learn More

  10. Cellular Therapy in Oncology Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 164 companies plus partners who are today developing 272 cellular therapy drugs in 577 developmental projects in cancer across 92 different targets. In addition, there are 7 suspended drugs and another 66 drugs where development has been ceased. Learn More

  11. Cancer Vaccines: From First-in-Class to Best-in-Class?

    Regular Price: $1,950.00

    Special Price: $975.00

    Published by BioSeeker Group on Mar 19th, 2013
    In-depth pipeline analytics of cancer vaccine drugs showing you where the competition is, what is first-in-class and is first-in-class the best-in-class?, Indication expansion opportunities and much more Learn More

  12. Cancer Peptides: From First-in-Class to Best-in-Class?

    Regular Price: $2,450.00

    Special Price: $1,225.00

    Published by BioSeeker Group on Jan 7th, 2013
    In-depth pipeline analytics of peptide drugs in oncology showing you where the Competition is, What is first-in-class and Is First-in-Class the Best-in-Class?, Indication expansion opportunities and much more Learn More

  13. Cancer Antibodies: Drug Target Atlas and Competitive Outlook

    Regular Price: $2,450.00

    Special Price: $1,225.00

    Published by BioSeeker Group on Nov 1st, 2012
    This report is a new and unique way of stratifying and analyzing the global antibody pipeline in cancer towards personalized medicine and presents actionable analysis Learn More

  14. Biologicals in Oncology Drug Pipeline Update

    $3,675.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 1371 companies plus partners who are today developing 2823 biological drugs in 6088 developmental projects in cancer across 801 different targets. In addition, there are 25 suspended drugs and another 1050 drugs where development has been ceased. Learn More

  15. Antibody Drug Target Atlas in Oncology - Where to Commercialize in a Crowded Market Place?

    $2,450.00
    Published by BioSeeker Group on Mar 1st, 2010
    This report comprises defined and up to date development strategies for 441 antibody drugs (993 projects) within the portfolio of 168 investigators, from Ceased to Marketed. The report extensively analyses 225 identified targets of antibody drugs, organized into 234 drug target profiles, and assesses them in 69 different cancer indications. Learn More

  16. Antibodies in Oncology: Analytical Tool

    $4,750.00
    Published by BioSeeker Group on Aug 22nd, 2016
    This Analytical Tool transforms your computer’s desktop into a high capacity workbench within the area of antibodies in oncology. It supports you in making reports, presentations and preparing conference attendance and it is all done via an easy to use ’point and click’ interface. Learn More

  17. Antibodies in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 542 companies plus partners who are today developing 1308 antibody drugs in 3051 developmental projects in cancer across 414 different targets. In addition, there are 4 suspended drugs and another 407 drugs where development has been ceased. Learn More

17 Item(s)

per page

Set Ascending Direction